Leveraging virtual technology to keep customers connected during COVID-19
Products & Services Feature Stories
Triple Combination Parasiticide Wins Industry Award
At Zoetis, we understand the special bond shared between people and their pets – and the importance of keeping our canine companions happy and healthy. Today we will focus on how we care for dogs from a dermatology perspective, just one of the many core areas of focus for Zoetis.
The U.S. Food and Drug Administration (FDA) has approved Simparica™, a once-monthly chewable flea and tick medication for dogs.
Clint Lewis, Executive Vice President and President, International Operations at Zoetis, shares his insights on the critical role that animal health plays in creating a safe and abundant food supply for a growing global population.
Zoetis marked the completion of a 19,000-square-foot, three-story expansion at its manufacturing site in Lincoln, Nebraska.
First targeted antibody therapy approved for control of clinical signs of atopic dermatitis in dogs
On September 2, the U.S. Department of Agriculture (USDA) granted Zoetis a conditional license for a vaccine to help fight porcine epidemic diarrhea virus (PEDv) in pigs.
This month, Zoetis launched EnlightTM, a new online, comprehensive management tool designed to help dairy producers who own Holstein cattle more efficiently manage herd genetics.
Targeting the global poultry industry's more than $3 billion in annual losses to coccidiosis, Zoetis introduced Rotecc™ Coccidiosis Management on January 28
In January, Zoetis launched the first and only Janus Kinase (JAK) inhibitor for veterinary use in the United States and Europe.
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States
Regulatory constraints and medical practices vary from location to location. Consequently, the information provided on the site in which you enter may not be suitable for use at your location.